En lidt længere sommer special, hvor vi dykker ned i noget der måske kan være lidt sværere at slå to streger under. Facit er ikke så eksakt!Her er Karinas noter til dagens afsnit: Empati Definition:The ability to imagine oneself as another person is a sophisticated process. However, the basic capacity to recognize emotions in others may be innate[5]and may be achieved unconsciously. Empathy is not all-or-nothing; rather, a person can be more or less empathic toward another and empirical research

SPECIAL GUEST HOSTS! On this episode, we welcome two guest hosts: Sue Tschorn RN and Leilani Schnoor RN, both Medical Group Nursing Professional Development Practitioners. Sue and Leilani interview Patient and Family Advisors about how Joint Commission requirements affect their personal experiences in healthcare.

How Shared Experiences Can Drive Positive Humanism

Host: Ashley Baker, MSN, PMHNP Guest: Giancarlo Moscol, M.D. Metastatic breast cancer treatment isn't one-size-fits-all. Providers must carefully balance clinical outcomes, toxicity, and patient lifestyle and preferences. Dr. Giancarlo Moscol joins Ms. Ashley Baker to outline a structured, three-tiered decision-making process that weighs treatment efficacy, side effect burden, and real-world logistics like administration route and patient support systems. Dr. Moscol is an Associate

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Gloria Coronado, PhD Colorectal cancer screening saw significant disruptions during the COVID-19 pandemic, a challenge that has also been reflected during natural disasters such as hurricanes and wildfires. Dr. Gloria Coronado joins Dr. Charles Turck to discuss how these kinds of crises impact screening rates and how a focus on community-based care, telehealth and home-based testing, and targeted efforts for underserved populations

Host: Aristides Maniatis, MD Guest: Kari Hosack Guest: Meagan Broeckert Guest: Sam Watson Join Dr. Aristides Maniatis for this Patient-Clinician Connection, a case-based activity that explores the full spectrum of care in Growth Hormone Deficiency. Through real patient and caregiver dialogues, this program teaches clinicians how to identify early signs of GHD, make accurate diagnoses, navigate pediatric-to-adult care transitions, and manage the switch from daily to

Ann Yeh, Professor of Paediatrics and neurologist in Toronto, Canada, highlights the global considerations in preventing MS disease progression in young people with MS.

CME credits: 0.25 Valid until: 29-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/adcs-across-the-spectrum-of-her2-expression-in-metastatic-breast-cancer/32202/ In this Virtual Case Clinic, explore three patient case examples with Dr. Mahtani as she demonstrates the application of the latest clinical evidence in HER2-positive, HER2-low, and HER2-ultralow metastatic breast cancer. By illustrating the use of antibody-drug conjugates in HER2-expressing disease, participants

Aroha to Tasman - NCC climate lens – International Court of Justice special – the Advisory Opinion is a BIG deal – from 27 Pacific law students to the world’s highest court – what was the ICJ addressing? – how did they respond? – how might we look on this? – a word form Ralph Regenvanu, Vanuatu’s special Climate change and environmental envoy. https://climatemattersnz.substack.com/p/climate-matters-icj-special

Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center as well as a Professor of

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it’s also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it’s important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there’s a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared

Guest: Reid Ness, MD The NCCN Guidelines for Colorectal Cancer Screening recently provided updates for patients at average and increased risk—most notably, lowering the recommended starting age from 50 to 45. Hear Dr. Reid Ness walk through the updates in depth, providing insight on screening protocols for different patient populations. Dr. Ness is an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, Tennessee, faculty with the Vanderbilt Ingram

Episode OverviewIn this episode of the Solar Maverick Podcast, I speak with Lee Keshishian, the Founder & CEO of Civic Renewables. We dive into his 18+ year journey in residential solar—from founding Clean Currents to scaling Tesla/SolarCity’s East Coast operations and now building a national network of trusted local solar installers. Lee shares insights on what it takes to grow resilient clean energy businesses and how Civic is raising the bar for solar quality and local impact. Benoy

In his weekly clinical update, Dr. Griffin with Vincent Racaniello chat about how flies transmit H5N1 to humans via their feet and milk, the recent pertussis oubreak and measles epidemic before Dr. Griffin discusses monoclonal antibody therapy can enrich for RSV variants before deep diving into recent statistics on RSV, influenza and SARS-CoV-2 infections the Wasterwater Scan dashboard, whether or not the NB.1.8.1 should be included in the fall 2025 vaccines, the effectiveness of Sinopharm’s

Dr. Tess Russo is an Assistant Professor in the Department of Geosciences at The Pennsylvania State University. Tess is a hydrologist which means she studies water. Her research examines how water moves, how much of it there is in the world, and how the actions of humans change how water moves in the world. Tess has been spending a lot of time doing home renovations. When she's not working on her house, she likes to visit family and travel. She received her PhD in Earth and Planetary Sciences from

#262: Tracie and Jennifer Mowdy [from the Literary Cat Bookstore and Cat Lounge] discuss the international bestseller "We'll Prescribe You a Cat" by Syou Ishida, translated from the Japanese, which strikes them as a metaphorical fable about how cats can teach us important lessons.

The Science of Happiness at Work: What Really Makes Us Thrive

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks with Dr. Matthew Lunning about the realities of patient selection, safety, and access. Dr. Lunning is an Associate Professor in the